Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Tel Aviv
SEC filing record 1 source field available
Fiscal year end
31 December
Chemomab Therapeutics Ltd. has filed 357 SEC EDGAR filings since 07 Nov 2011

SEC filing history

Showing 1-25 of 357 matching filings.

Per page
25
Current page
1
SCHEDULE 13D/A File 005-86953

SCHEDULE 13D/A filing

Filing date
09 Sep 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
01 Sep 2026
Reporting date
27 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G File 005-86953

SCHEDULE 13G filing

Filing date
13 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A File 005-86953

SCHEDULE 13G/A filing

Filing date
10 Aug 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D File 005-86953

SCHEDULE 13D filing

Filing date
16 Jul 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-38807

6-K

Filing date
08 Jul 2026
Reporting date
08 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
03 Jun 2026
Reporting date
01 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-38807

6-K

Filing date
02 Jun 2026
Reporting date
02 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
01 Jun 2026
Reporting date
29 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-38807

6-K

Filing date
14 May 2026
Reporting date
14 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-38807

6-K

Filing date
06 May 2026
Reporting date
06 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-38807

6-K

Filing date
28 Apr 2026
Reporting date
28 Apr 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3 filing

Filing date
10 Apr 2026
Reporting date
18 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
10 Apr 2026
Reporting date
18 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3 filing

Filing date
10 Apr 2026
Reporting date
18 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3 filing

Filing date
10 Apr 2026
Reporting date
18 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3 filing

Filing date
10 Apr 2026
Reporting date
18 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3 filing

Filing date
10 Apr 2026
Reporting date
18 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3 filing

Filing date
31 Mar 2026
Reporting date
18 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
3

3 filing

Filing date
31 Mar 2026
Reporting date
18 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-38807

6-K

Filing date
20 Mar 2026
Reporting date
20 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-38807

6-K

Filing date
19 Mar 2026
Reporting date
19 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A File 005-86953

SCHEDULE 13G/A filing

Filing date
17 Feb 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .